- Investing.com
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatrists, primary care physicians, and other clinicians at the point-of care to objectively detect, stage, and monitor peripheral neuropathies. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts. As of May 1, 2025, NeuroMetrix, Inc. operates as a subsidiary of electroCore, Inc.
Metrics to compare | NURO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNUROPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.2x | −2.9x | −0.5x | |
PEG Ratio | −0.03 | −0.21 | 0.00 | |
Price/Book | 0.7x | 2.4x | 2.6x | |
Price / LTM Sales | 3.1x | 2.5x | 3.1x | |
Upside (Analyst Target) | - | 73.0% | 48.6% | |
Fair Value Upside | Unlock | 21.8% | 8.9% | Unlock |